SearchDictionaryMobileLogin

Rhian M Touyz Selected Research

Hypertension (High Blood Pressure)

06/2008Reactive oxygen species and hypertension: a complex association.
06/2008Thioredoxin in vascular biology: role in hypertension.
03/2008Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension.
02/2008NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities.
02/2008Renal Redox-Sensitive Signaling, but Not Blood Pressure, Is Attenuated by Nox1 Knockout in Angiotensin II-Dependent Chronic Hypertension.
01/2008Endothelin, sex and hypertension.
12/2007Magnesium transport in hypertension.
04/2007Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice.
03/2007Vascular signaling through cholesterol-rich domains: implications in hypertension.
02/2007Role of magnesium in hypertension.
09/2006Reactive oxygen species and vascular remodelling in hypertension: still alive.
07/2006Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension.
03/2006Magnesium and hypertension.
02/2006Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms.
07/2005Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II.
04/2005Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase.
03/2005Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II.
01/2005Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: Effect of angiotensin II and role of insulinlike growth factor-1 receptor transactivation.
09/2004Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?
06/2004Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist.
05/2004SAM68: a downstream target of angiotensin II signaling in vascular smooth muscle cells in genetic hypertension.
11/2003Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension.
10/2003ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension.
10/2003Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
10/2003Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension.
09/2003Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade.
08/2003Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice.
06/2003Role of endothelin in human hypertension.
05/2003Reactive oxygen species in vascular biology: role in arterial hypertension.
04/2003The role of angiotensin II in regulating vascular structural and functional changes in hypertension.
02/2003Inhibitors of Na+/Mg2+ exchange activity attenuate the development of hypertension in angiotensin II-induced hypertensive rats.
01/2003Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
11/2002Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats: role of reactive oxygen species.
08/2002Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension.
01/2002Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats.

Articles by Research Topic

Disease

35Hypertension (High Blood Pressure)
06/2008 - 01/2002
6Stroke (Strokes)
12/2006 - 01/2002
5Inflammation
04/2008 - 12/2002
3Fibrosis (Cirrhosis)
04/2008 - 10/2003
2Cardiomegaly (Heart Hypertrophy)
10/2008 - 04/2005
1Heart Failure
07/2008
1Hyperaldosteronism (Conn Syndrome)
02/2005
1Tissue Adhesions
04/2004
1Hypertrophy
05/2003

Drug/Important Bio-Agent (IBA)

17Angiotensin IIIBA
02/2008 - 02/2003
7Reactive Oxygen Species (Oxygen Radicals)IBA
06/2008 - 11/2002
7MagnesiumIBA
04/2008 - 11/2002
4Desoxycorticosterone (DOCA)FDA Link
04/2007 - 10/2003
4NADPH Oxidase (NAD(P)H oxidase)IBA
02/2006 - 05/2003
3Endothelins (Endothelin)IBA
01/2008 - 01/2003
3PPAR alphaIBA
10/2003 - 12/2002
2ThioredoxinsIBA
10/2008 - 06/2008
2AldosteroneIBA
04/2008 - 08/2002
2Macrophage Colony-Stimulating FactorIBA
04/2007 - 10/2005
1candesartanIBA
07/2008
1OxidoreductasesIBA
02/2008
1NADP (NADPH)IBA
02/2008
1CholesterolIBA
03/2007
1Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2006
1Protein Kinases (Protein Kinase)IBA
12/2006
1AngiotensinsIBA
10/2005
1Type 2 Angiotensin ReceptorIBA
05/2005
1rho-Associated KinasesIBA
05/2005
1CalciumIBA
02/2005
1des-Asp(1)-des-Arg(2)-Ile(5)- angiotensin IIIBA
06/2004
1eplerenone (Inspra)FDA LinkGeneric
06/2004
1Superoxides (Superoxide)IBA
10/2003
1Follicle Stimulating Hormone (Follitropin)IBA
10/2003
1Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA
08/2003
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
08/2002
1Endothelin-1 (Endothelin 1)IBA
08/2002
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2002
1Endothelin A ReceptorIBA
06/2002
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
06/2002
1CollagenIBA
06/2002
1Superoxide DismutaseIBA
01/2002